Filgrastim biosimilar - Adello Biologics

Drug Profile

Filgrastim biosimilar - Adello Biologics

Latest Information Update: 21 Nov 2016

Price : $50

At a glance

  • Originator Therapeutic Proteins International
  • Developer Adello Biologics
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Neutropenia

Most Recent Events

  • 16 Nov 2016 Therapeutic Proteins International is now called Adello Biologics
  • 24 Jun 2015 Research is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top